Multiple sclerosis linked to lower risk for Alzheimer’s disease pathology
By
Haymarket Media
Aug 30, 2024
A lower rate of amyloid-β plasma biomarker positivity was seen in multiple sclerosis patients compared with non-MS controls.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Nearly 7 million Americans have Alzheimer’s, and caregivers are stressed
Mar 20, 2024
Nearly 7 million American seniors are living with Alzheimer’s dementia, placing a huge strain on both personal caregivers and the US healthcare system, according to a new Alzheimer’s Association...
Stress, depression linked to MCI, Alzheimer’s disease
Oct 20, 2023
Chronic stress and depression are independent risk factors and have an additive effect when combined.
Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Finger prick, venous blood can ID key Alzheimer’s disease biomarkers
Jul 20, 2023
Capillary and venous dry blood spot can identify glial fibrillary acidic protein, neurofilament light and phosphorylated tau.
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.